NasdaqCM:IMNMBiotechs
How Immunome’s (IMNM) Varegacestat NDA and Phase 3 Data Could Reshape Its Desmoid Tumor Story
Immunome has submitted a New Drug Application to the FDA for varegacestat, an oral once-daily gamma secretase inhibitor for adults with desmoid tumors, backed by a global Phase 3 RINGSIDE trial that met its primary and key secondary endpoints.
A key insight is that RINGSIDE is the largest randomized study conducted in this rare tumor type, with data selected for oral presentation at the 2026 ASCO Annual Meeting, highlighting the clinical community’s interest in varegacestat’s profile.
We’ll...